“GLP-1s paralyze your stomach and give you gastroparesis.”
What the evidence shows
GLP-1 medicines deliberately slow how fast the stomach empties — that is part of how they curb appetite, it is documented in the trials, and "delayed gastric emptying" is named on the FDA label. A 2023 health-claims study (Sodhi et al., JAMA) found people using GLP-1s for weight loss had a higher rate of a recorded gastroparesis diagnosis than people on another weight-loss drug (bupropion-naltrexone), with an adjusted hazard ratio of about 3.67 (95% CI, 1.15–11.90), so a real but uncommon signal exists.
What we still don’t know
We do not have solid numbers on how often lasting, clinically serious gastroparesis actually occurs. The Sodhi study counted billing/diagnosis codes rather than confirmed gastric-emptying tests, the confidence interval was wide (barely excluding no effect), and it could not prove cause. Whether the slowing fully resolves in everyone after stopping is not firmly established, though endocrinology reviews report the effect partly fades over months of use (tachyphylaxis) and generally eases when the dose is lowered or the drug is stopped.
Why the claim misleads
"Paralyze your stomach" reframes an intended, dose-related, usually-reversible slowdown as permanent organ damage. Slowed emptying is expected and most often improves with time or dose adjustment, and confirmed persistent gastroparesis appears uncommon — but new, severe, or ongoing vomiting and abdominal pain are red flags that warrant a clinician promptly, not a forum.
Graded by The Peptide Era · evidence, not hype